High levels of PD-L1 expression have been associated with improved responses to anti-PD-1/PD-L1 therapy in multiple cancer types, including melanoma, non-small cell lung cancer, urothelial carcinoma, triple-negative breast cancer, gastric adenocarcinoma, and ovarian cancer[117,118]. This evidence concerns the gene CD274 and gastric adenocarcinoma.